CRDF
Cardiff Oncology IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$121.70M
P/E Ratio
—
EPS
$-0.67
Beta
1.36
52W High
$4.56
52W Low
$1.48
50-Day MA
$1.69
200-Day MA
$2.09
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Cardiff Oncology Inc
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | 525,000 |
| Gross Profit (TTM) | $-31.09M |
| EBITDA | $-47.07M |
| Operating Margin | -31341.00% |
| Return on Equity | -84.80% |
| Return on Assets | -44.30% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.51 |
| Price-to-Book | 3.51 |
| Price-to-Sales (TTM) | 231.81 |
| EV/Revenue | 145.31 |
| EV/EBITDA | -3.66 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -62.40% |
| Shares Outstanding | $68.37M |
| Float | $66.71M |
| % Insiders | 5.91% |
| % Institutions | 32.86% |
Historical Volatility
HV 10-Day
43.16%
HV 20-Day
51.85%
HV 30-Day
56.34%
HV 60-Day
55.47%
HV Rank
25.4%
Volatility is currently contracting
Analyst Ratings
Consensus ($7.69 target)
1
Strong Buy6
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026